Capital World Investors, a registered investment adviser, initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 42,872,129 shares of the Healthcare company, valued at approximately $5.3B as of the filing date.
Gilead Sciences, Inc.'s stock currently trades at $152.88 with a market capitalization of $152.9B.